KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) FCF Margin (2016 - 2025)

NovoCure (NVCR) has disclosed FCF Margin for 12 consecutive years, with 13.13% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 545.0% to 13.13% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11.55% through Dec 2025, down 11.0% year-over-year, with the annual reading at 11.55% for FY2025, 11.0% down from the prior year.
  • FCF Margin hit 13.13% in Q4 2025 for NovoCure, down from 8.92% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 17.64% in Q2 2021 to a low of 31.3% in Q1 2024.
  • Historically, FCF Margin has averaged 6.2% across 5 years, with a median of 7.79% in 2022.
  • Biggest five-year swings in FCF Margin: tumbled -3363bps in 2023 and later soared 2067bps in 2024.
  • Year by year, FCF Margin stood at 0.1% in 2021, then crashed by -8189bps to 7.89% in 2022, then plummeted by -102bps to 15.98% in 2023, then skyrocketed by 52bps to 7.68% in 2024, then plummeted by -71bps to 13.13% in 2025.
  • Business Quant data shows FCF Margin for NVCR at 13.13% in Q4 2025, 8.92% in Q3 2025, and 13.49% in Q2 2025.